COVID Treatment

Analysis indicates 4 peptides had significant or nearly significant seropositivity, all of which were associated with membrane and spike proteins of SARS-COVID-2.

COVID-19 infection was significantly associated with increased risks of several conditions, including loss of smell and taste, concentration, and memory impairment.

Providers use "Kitchen Sink Approach" because cure proves elusive, symptomatic treatment is sketchy.

The risk of severe COVID-19 continues to outweigh the rare risk of post-vaccination myocarditis.

An overview of current theses and research surrounding the pathogenesis, presentation, and treatment of COVID-19 in children.

In addition to the physical symptoms of long COVID, patients have reported vocal, verbal, and cognitive issues that disrupt their ability to communicate.

Pharmacists have been increasingly recognized as key partners in the clinical services needed to manage the pandemic.

Similar symptoms often make it difficult for patients to tell the contagious respiratory conditions apart.

By leveraging do-it-yourself testing momentum, community-based and retail pharmacies can solidify their position as health care hubs with a category management approach that enhances the consumer experience and boosts store relevance and revenue.

Pharmacists concluded that the workflow could be implemented for any drugs that are in short supply.

Individuals who had COVID-19 were 55% more likely to develop epilepsy or seizures over the following 6 months than those who had influenza.

Findings support the potential protective association of vaccination in reducing long COVID, although it does not appear to eliminate the risk.

Approximately 2 years after patients were infected with COVID-19, non-hospitalized patients suffered from post-COVID-19 symptoms nearly 8% more than hospitalized patients.

Although long-term health issues from COVID-19 are a major public health concern, evidence on post-acute COVID-19 syndrome, or post-COVID-19, is still limited, specifically among children and adolescents.

Individuals with COVID-19 reinfections were twice as likely to die and three times more likely to be hospitalized than those who did not have COVID-19 multiple times.

In recent years, pharmacist roles have evolved as critically important caregivers who increasingly provide essential health care services far beyond medication dispensing.

New COVID-19 variants are always cause for concern but are not a cause for panic.

A session presenter at the ASCP 2022 Annual Meeting explained how the COVID-19 pandemic significantly magnified the importance of infection prevention and control practices in long-term care.

In addition to the ongoing COVID-19 pandemic, significant public health concerns include opioid overdoses, maternal mortality disparities, and climate change.

Pharmacy leaders and academics have been begging the profession to evolve for decades. It took a pandemic to make it happen.

Double-digit inflation, low reimbursement rates, and staffing shortages present obstacles.

Last year in particular, pharmacists played a greater role in patient care with an increased workload as they connected patients, providers, and payers.

Highest prevalence is seen among adults, outpatients, and women and can cause persistent severe anosmia or hyposmia, findings indicate.

Prior infection with SARS-CoV-2 decreased the risk of being reinfected with Omicron among unvaccinated and vaccinated individuals.

The risk of severe COVID-19 breakthrough infection was stronger with age and some comorbidities—the findings can inform antiviral distribution to prevent death or respiratory failure.

Many people wanted life to feel normal during the COVID-19 pandemic; however, this reason, among many, resulted in people not adhering to public health measures in the United States.

Because we need to be prepared and respond to future crises, making these changes permanent is a top priority for the profession of pharmacy.

Latest Information is key to helping patients stay healthy amid continuously changing landscape.

At month 6 post-COVID-19 infection, 123 patients received a diagnosis of type 1 diabetes (T1D) and only 72 were diagnosed with T1D at 6 months post-non-COVID-19 respiratory infection.

FDA revises emergency use authorization to grant prescribing authority for Pfizer’s Paxlovid antiviral treatment for COVID-19.